Pregled bibliografske jedinice broj: 1253468
Reimbursed medication adherence enhancing interventions in 12 european countries: current state of the art and future challenges
Reimbursed medication adherence enhancing interventions in 12 european countries: current state of the art and future challenges // Frontiers in pharmacology, 13 (2022), 944829, 17 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1253468 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Reimbursed medication adherence enhancing
interventions in 12 european countries: current
state of the art and future challenges
Autori
Przemysław Kardas, Martina Bago, Pilar Barnestein- Fonseca, Kristina Garuolienė, Anne Gerd Granas, João Gregório, Maja Ortner Hadžiabdić, Barbora Kostalova, Francisca Leiva-Fernández, Pawel Lewek, Katerina Mala-Ladova, Marie Paule Schneider, Job FM Van Boven, Daisy Volmer, Ioli Ziampara, Tamás Ágh
Izvornik
Frontiers in pharmacology (1663-9812) 13
(2022);
944829, 17
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
chronic therapies, medication adherence-enhancing interventions, MAEIs
Sažetak
Background: Medication non-adherence jeopardises the effectiveness of chronic therapies and negatively affects financial sustainability of healthcare systems. Available medication adherence-enhancing interventions (MAEIs) are utilised infrequently, and even more rarely reimbursed. The aim of this paper was to review reimbursed MAEIs across selected European countries. Methods: Data on reimbursed MAEIs were collected from European countries at the ENABLE Cost Action expert meeting in September 2021. The identified MAEIs were analysed and clustered according to their characteristics, direct vs. indirect relation to adherence, and the targeted adherence phase. Results: Out of 12 contributing countries, 10 reported reimbursed MAEIs, 28 in total, of which 20 were identified as MAEIs targeting adherence directly. Reimbursed MAEIs were most often performed by either doctors (n = 6), nurses (n = 6), or pharmacists (n = 3). The most common types of MAEIs were education (n = 6), medication regimen management (n = 5), and adherence monitoring feedback (n = 4). Only seven reimbursed MAEIs were technology-mediated, whereas 11 addressed two interlinked phases of medication adherence, i.e., implementation and persistence. Conclusion: Our review highlights the scarcity of reimbursed MAEIs across the selected European countries, and calls for their more frequent use and reimbursement.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus